Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in ...

Market Context Silexion (SLXN) market analysis \| market outlook analysis, institutional ownership, trading signals. Traders ...

SIL204 demonstrated dose-dependent inhibition of up to 94% in pancreatic cancer cells harboring KRAS G12D mutations at nanomolar concentrations. SIL204 showed comparable efficacy of approximately 97% ...

Short interest in Silexion Therapeutics Corp (NASDAQ:SLXN) increased during the last reporting period, rising from 359.10K to 619.43K. This put 7.56% of the company's publicly available shares short.

) has been revised to $6.12 / share. This is a decrease of 33.33% from the prior estimate of $9.18 dated February 21, 2026. The price target is an average of many targets provided by analysts. The ...

Silexion (SLXN) market outlook | growth forecasts and investor confidence remain in focus. Silexion Therapeutics Corp (SLXN) ...

Silexion Therapeutics Corp (NASDAQ:SLXN) has announced breakthrough preclinical results for its next-generation RNA interference (RNAi) therapy, SIL204, showing potent anti-tumor effects across three ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Silexion’s Revolutionary RNAi approach demonstrates powerful anti-tumor activity across three major KRAS-driven cancer types; Inhibition rate of ~90% observed in GP2D human colorectal cancer cells; ...